Upgrade to SI Premium - Free Trial

Corcept Therapeutics (CORT)

79.91 -1.84 (2.25%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/5/26)

Latest Headlines

Form 4 CORCEPT THERAPEUTICS For: Jun 16 Filed by: WILSON JAMES N June 18, 2026 4:31 PM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: Jun 17 Filed by: MAHONEY DAVID L June 18, 2026 4:31 PM - SEC Filing Form 8-K CORCEPT THERAPEUTICS For: Jun 17 June 17, 2026 4:37 PM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: Jun 15 Filed by: Mokari Atabak June 17, 2026 4:30 PM - SEC Filing Corcept resubmits NDA for relacorilant to treat Cushing's syndrome June 17, 2026 4:28 PM - StreetInsider Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome June 17, 2026 4:28 PM - BizWire Form 144 CORCEPT THERAPEUTICS Filed by: MAHONEY DAVID L June 16, 2026 3:06 PM - SEC Filing Form 144 CORCEPT THERAPEUTICS Filed by: WILSON JAMES N June 16, 2026 1:56 PM - SEC Filing Corcept reports improved diabetes outcomes with Korlym and GLP-1 combo June 6, 2026 4:48 PM - StreetInsider Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym® June 6, 2026 4:45 PM - BizWire Form 4 CORCEPT THERAPEUTICS For: Jun 02 Filed by: Guyer William June 4, 2026 4:49 PM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: Jun 01 Filed by: Lyon Joseph Douglas June 3, 2026 7:32 PM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: Jun 01 Filed by: Guyer William June 3, 2026 7:25 PM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: Jun 01 Filed by: Maduck Sean June 3, 2026 7:21 PM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: Jun 01 Filed by: Mokari Atabak June 3, 2026 7:20 PM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: Jun 01 Filed by: Robb Gary Charles June 3, 2026 7:15 PM - SEC Filing Form 8-K CORCEPT THERAPEUTICS For: May 19 June 3, 2026 8:00 AM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: May 29 Filed by: BELANOFF JOSEPH K June 2, 2026 4:06 PM - SEC Filing Form 144 CORCEPT THERAPEUTICS Filed by: Guyer William June 2, 2026 2:25 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on Corcept Therapeutics (CORT) June 2, 2026 6:56 AM - StreetInsider Form 144 CORCEPT THERAPEUTICS Filed by: Mokari Atabak June 1, 2026 5:51 PM - SEC Filing Form 144 CORCEPT THERAPEUTICS Filed by: BELANOFF JOSEPH K June 1, 2026 11:41 AM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: May 27 Filed by: Lyon Joseph Douglas May 29, 2026 6:12 PM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: May 27 Filed by: Maduck Sean May 29, 2026 6:03 PM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: May 27 Filed by: WILSON JAMES N May 29, 2026 5:56 PM - SEC Filing Corcept presents survival data for Lifyorli in ovarian cancer at ASCO May 29, 2026 4:36 PM - StreetInsider Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure May 29, 2026 4:33 PM - BizWire Form S-8 CORCEPT THERAPEUTICS May 29, 2026 4:30 PM - SEC Filing Form 8-K CORCEPT THERAPEUTICS For: May 21 May 28, 2026 4:49 PM - SEC Filing Corcept Therapeutics (CORT) PT Raised to $135 at Canaccord May 28, 2026 7:39 AM - StreetInsider Corcept Therapeutics (CORT) PT Raised to $95 at H.C. Wainwright May 28, 2026 7:07 AM - StreetInsider Form 144 CORCEPT THERAPEUTICS Filed by: Maduck Sean May 27, 2026 6:08 PM - SEC Filing Corcept to resubmit drug application for Cushing's syndrome treatment May 27, 2026 8:01 AM - StreetInsider Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome May 27, 2026 8:00 AM - BizWire Form 4 CORCEPT THERAPEUTICS For: May 21 Filed by: BAKER G LEONARD JR May 26, 2026 5:41 PM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: May 21 Filed by: Alton Gregg H May 26, 2026 5:40 PM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: May 21 Filed by: WILSON JAMES N May 26, 2026 5:36 PM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: May 21 Filed by: Swisher Daniel N JR May 26, 2026 5:35 PM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: May 21 Filed by: Murray Joshua M. May 26, 2026 5:33 PM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: May 21 Filed by: MAHONEY DAVID L May 26, 2026 5:31 PM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: May 21 Filed by: Park Kimberly May 26, 2026 5:29 PM - SEC Filing Form 144 CORCEPT THERAPEUTICS Filed by: Lyon Joseph Douglas May 20, 2026 12:47 PM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: May 13 Filed by: Robb Gary Charles May 15, 2026 6:59 PM - SEC Filing UBS Upgrades Corcept Therapeutics (CORT) to Neutral May 13, 2026 4:27 AM - StreetInsider Form 4 CORCEPT THERAPEUTICS For: May 05 Filed by: Guyer William May 7, 2026 4:33 PM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: May 01 Filed by: BELANOFF JOSEPH K May 5, 2026 4:31 PM - SEC Filing Form 144 CORCEPT THERAPEUTICS Filed by: Guyer William May 5, 2026 11:14 AM - SEC Filing Corcept Therapeutics (CORT) PT Raised to $75 at H.C. Wainwright May 4, 2026 7:28 AM - StreetInsider Form 144 CORCEPT THERAPEUTICS Filed by: BELANOFF JOSEPH K May 1, 2026 12:30 PM - SEC Filing Corcept Therapeutics (CORT ) PT Raised to $88 at Piper Sandler May 1, 2026 7:37 AM - StreetInsider Corcept Therapeutics (CORT) Misses Q1 EPS by 19c ; Offers Guidance May 1, 2026 2:00 AM - StreetInsider Form 10-Q CORCEPT THERAPEUTICS For: Mar 31 April 30, 2026 4:19 PM - SEC Filing Form 8-K CORCEPT THERAPEUTICS For: Apr 30 April 30, 2026 4:16 PM - SEC Filing Corcept reports survival benefit in ALS drug trial after two years April 30, 2026 4:06 PM - StreetInsider Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis April 30, 2026 4:05 PM - BizWire Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update April 30, 2026 4:05 PM - BizWire Form 4 CORCEPT THERAPEUTICS For: Apr 22 Filed by: WILSON JAMES N April 24, 2026 4:30 PM - SEC Filing Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call April 23, 2026 4:05 PM - BizWire Form SCHEDULE 13G/A CORCEPT THERAPEUTICS Filed by: INGALLS & SNYDER LLC April 21, 2026 4:21 PM - SEC Filing Corcept to present ROSELLA trial data at ASCO 2026 April 21, 2026 1:09 PM - StreetInsider Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026 April 21, 2026 1:09 PM - BizWire Form DEF 14A CORCEPT THERAPEUTICS For: Apr 17 April 17, 2026 4:09 PM - SEC Filing Corcept presents survival data for ovarian cancer drug Lifyorli April 10, 2026 4:45 PM - StreetInsider Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in P April 10, 2026 4:45 PM - BizWire Form 4 CORCEPT THERAPEUTICS For: Apr 07 Filed by: Guyer William April 8, 2026 7:35 PM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: Apr 06 Filed by: WILSON JAMES N April 8, 2026 7:30 PM - SEC Filing Form 144 CORCEPT THERAPEUTICS Filed by: Guyer William April 7, 2026 1:27 PM - SEC Filing Corcept finds hypercortisolism in 27% of resistant hypertension patients March 30, 2026 4:21 AM - StreetInsider Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session March 28, 2026 2:45 PM - BizWire Form 4 CORCEPT THERAPEUTICS For: Mar 25 Filed by: BELANOFF JOSEPH K March 27, 2026 4:28 PM - SEC Filing Form SCHEDULE 13G/A CORCEPT THERAPEUTICS Filed by: VANGUARD GROUP INC March 26, 2026 5:43 PM - SEC Filing Wolfe Research Upgrades Corcept Therapeutics (CORT) to Peerperform March 25, 2026 6:03 PM - StreetInsider Form 144 CORCEPT THERAPEUTICS Filed by: BELANOFF JOSEPH K March 25, 2026 3:55 PM - SEC Filing Form 8-K CORCEPT THERAPEUTICS For: Mar 25 March 25, 2026 1:32 PM - SEC Filing Corcept Therapeutics (CORT) PT Raised to $110 at Canaccord March 25, 2026 1:19 PM - StreetInsider FDA approves Corcept's Lifyorli for platinum-resistant ovarian cancer March 25, 2026 12:43 PM - StreetInsider FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer March 25, 2026 12:43 PM - BizWire FDA approves Corcept's relacorilant combination for platinum-resistant ovarian cancer March 25, 2026 10:33 AM - StreetInsider Form 4 CORCEPT THERAPEUTICS For: Mar 20 Filed by: WILSON JAMES N March 24, 2026 4:56 PM - SEC Filing Form 4 CORCEPT THERAPEUTICS For: Mar 20 Filed by: Guyer William March 24, 2026 4:55 PM - SEC Filing Full Article List